poisar

Stock

BioRestorative Therapies, Inc. Common Stock (NV) BRTX

$0.22+3.72%

Overview

BRTX market data

Price History

BRTX price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.58
Diluted earnings per share over the trailing twelve months.
Beta
0.82
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-3,089.6%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.16 – $1.89
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $5.6M · P/B 29.24 · P/S 15.68.

Company News

9 captured
Biorestorative Therapies Suspends All Orders, Shipments Of ExoCR, BioX Biocosmeceutical Product Lines Effective Immediately, On Aug 7; Conducting Review Of The Documentation, Sourcing, Regulatory Status Associated With Suspended Products; Has Not Made Decision To Discontinue Suspended Product LinesBenzinga · Aug 14, 2026, 8:48 PM
8-K filing — BioRestorative Therapies, Inc. (BRTX)SEC EDGAR · Aug 14, 2026, 8:15 PM
12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · Aug 7, 2026, 9:05 PM
BioRestorative Therapies Says Lance Alstodt Resigns As President, CEO, Chairman And All Other Positions Effective July 13, 2026; Robert Kristal Resigns As CFO And All Other Positions; Katharyn Field Appointed As CEO, President, And Interim CFOBenzinga · Jul 16, 2026, 9:45 PM
BioRestorative Therapies Completes Production For Its BRTX-100 Phase 2 Clinical Study To Support Current Clinical Development To Treat Chronic Lumbar Disc DiseaseBenzinga · Jun 25, 2026, 12:20 PM
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 ResultsBenzinga · May 27, 2026, 2:40 PM
Kaos Capital Acquires 4.9% Of Issued And Outstanding Common Stock Of BioRestorative Therapies; Terms UndisclosedBenzinga · May 27, 2026, 11:47 AM
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataGlobenewswire Inc · May 26, 2026, 3:15 PM
BioRestorative Therapies Doses Last Participant In Its Phase 2 Clinical Study Of BRTX-100 To Treat Chronic Lumbar Disc DiseaseBenzinga · May 26, 2026, 3:03 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock